Risk factors, outcomes, and predictors of therapeutic response in preterm infants with patent ductus arteriosus: A retrospective cohort study

This retrospective cohort study of 60 preterm infants with patent ductus arteriosus (PDA) identifies gestational age ≥28 weeks and antenatal corticosteroid exposure as key predictors of successful pharmacological closure, while demonstrating that effective treatment significantly reduces the high mortality rate associated with PDA, particularly in infants born before 28 weeks.

The Gist

Imagine a baby's heart is like a house with two main rooms: the left side (which pumps oxygen-rich blood to the body) and the right side (which sends blood to the lungs to get oxygen).

In a normal pregnancy, there is a special "backdoor" connecting these two rooms called the Ductus Arteriosus. This door is necessary while the baby is in the womb because the baby gets oxygen from the mother, not their own lungs. Once the baby is born and takes their first breath, this door is supposed to slam shut and seal up permanently within a few days.

The Problem: The Door That Won't Close
In some premature babies (born too early), this door gets stuck open. This is called a Patent Ductus Arteriosus (PDA).

Think of it like a leaky pipe in a house. Because the door is open, blood starts flowing the wrong way, rushing from the high-pressure left room back into the lungs. This causes two big problems:

1. The Lungs get flooded: They have to work too hard, making it hard for the baby to breathe.
2. The Body gets thirsty: The blood that should go to the brain and gut is getting stolen by the lungs, leaving the rest of the baby's body starved for oxygen.

The Study: What the Doctors Found
A team of doctors in Tunisia looked back at medical records from 2016 to 2019. They studied 60 premature babies who had this "stuck door" and were treated with medicine (either Ibuprofen or Paracetamol) to try to close it.

Here is what they discovered, using some simple comparisons:

1. The "Tiny vs. Small" Factor

The most important thing they found was how early the baby was born.

• The Analogy: Imagine trying to fix a broken window. If the window frame is brand new and sturdy (a baby born at 28+ weeks), the repair crew can fix it easily. But if the frame is made of wet tissue paper (a baby born before 28 weeks), it's incredibly fragile and hard to fix.
• The Finding: Babies born at 28 weeks or older had a much higher chance of the medicine working. Babies born before 28 weeks were in much more danger.

2. The "Pre-Game Prep" (Antenatal Steroids)

Before the baby is born, doctors sometimes give the mother special steroids to help the baby's lungs grow faster.

• The Analogy: Think of this like giving a runner a good breakfast and stretching session before a race.
• The Finding: Babies whose moms got this "pre-game prep" were much more likely to respond well to the medicine that closes the door. Only half of the moms in this study got this help, often because the babies were born too suddenly.

3. The Medicine Works (Mostly)

The doctors used two types of medicine: Ibuprofen (the classic choice) and Paracetamol (a newer, gentler alternative).

• The Result: The medicine worked like a charm in about 83% of the cases. The "leaky pipe" was sealed up, and the babies got better.
• The Catch: If the medicine didn't work the first time, or if the baby was very tiny, the situation became very serious.

4. The Stakes are High

This isn't just a minor inconvenience; it's life-or-death.

• The Danger: Because the blood is being stolen from the body, these babies are at high risk for bleeding in the brain (like a burst pipe in the ceiling) or damage to the gut.
• The Mortality Rate: Sadly, 35% of the babies in this study passed away. However, the risk was heavily tied to how small they were. Babies born before 28 weeks had an 82% chance of dying, while larger preemies had a much better chance.
• The Good News: If the medicine worked and the baby's breathing improved quickly, their chances of survival went up significantly.

The Big Takeaway

The doctors concluded that to save these babies, we need to:

1. Catch it early: Don't wait for the baby to get sick; check their hearts with an ultrasound (a camera for the heart) as soon as possible.
2. Prep the mom: Make sure moms get those steroid shots before birth to give the baby the best start.
3. Act fast: If the door is stuck, use medicine immediately.

In a nutshell: Premature babies often have a heart door that won't close. While medicine can usually fix it, the earlier the baby is born, the harder the fix becomes. The key to survival is catching the problem early and giving the baby the best possible start before they even arrive.

Technical Summary

1. Problem Statement

Patent Ductus Arteriosus (PDA) is a prevalent cardiovascular condition in preterm infants, affecting up to 70% of those born before 28 weeks gestation. While physiological closure typically occurs within 72 hours of birth, it often fails in preterm neonates due to impaired mechanisms triggered by lung expansion and placental cessation.

• Clinical Challenge: Persistent PDA leads to left-to-right shunting, causing pulmonary overcirculation and systemic hypoperfusion. This is associated with severe morbidities, including intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), pulmonary hemorrhage, and increased mortality.
• Management Controversy: Despite the clinical significance, management strategies remain debated. While indomethacin was historically standard, ibuprofen and paracetamol are now widely used. However, there is a lack of consensus on optimal screening (systematic vs. symptomatic), diagnostic criteria, and predictors of response to pharmacological therapy, particularly in resource-limited or specific regional settings.

2. Methodology

• Study Design: A retrospective, single-center cohort study conducted over a 4-year period (January 2016 – December 2019).
• Setting: Neonatal Intensive Care Unit (NICU) of a tertiary care center in Monastir, Tunisia.
• Population:
  • Total Screened: 2,154 preterm infants admitted to the NICU.
  • Inclusion Criteria: Infants with echocardiographically confirmed PDA who received pharmacological treatment (intravenous paracetamol or ibuprofen).
  • Final Sample Size: 60 infants (Incidence: 2.8% of screened preterms).
  • Exclusion Criteria: Infants with other congenital heart diseases, those managed conservatively without drugs, or those lacking echocardiographic confirmation.
• Data Collection: Variables included perinatal characteristics (gestational age, birth weight, antenatal corticosteroids), neonatal clinical course (respiratory distress, ventilation), PDA characteristics (diameter, shunt direction, LA/Ao ratio), treatment response, and outcomes (mortality, complications).
• Definitions:
  • Hemodynamically Significant PDA: Ductal diameter $\ge$ 1.5 mm, LA/Ao ratio $\ge$ 1.5, or clinical signs of hypoperfusion.
  • Clinical Improvement: Reduction in respiratory distress, improved oxygenation, or hemodynamic stabilization.
  • Treatment Failure: Persistence of hemodynamically significant PDA after the first course.
• Statistical Analysis: Descriptive statistics, Pearson's chi-square test for univariate analysis, and multivariable logistic regression to identify independent predictors of treatment response and mortality.

3. Key Contributions

• Predictive Modeling: The study identifies specific independent predictors for both therapeutic success (closure) and mortality in a real-world cohort, highlighting the critical roles of gestational age and antenatal corticosteroid exposure.
• Treatment Efficacy Comparison: It provides data on the efficacy of paracetamol versus ibuprofen in a setting where paracetamol was the dominant first-line agent (73.3% of cases), reporting a high closure rate.
• Risk Stratification: The research underscores the extreme vulnerability of infants born before 28 weeks, quantifying their significantly higher mortality and lower response rates compared to slightly more mature preterms.
• Screening Advocacy: It argues for the implementation of systematic echocardiographic screening in high-risk neonates rather than relying solely on clinical deterioration, noting that diagnosis was often delayed until clinical signs appeared.

4. Key Results

• Demographics: Mean gestational age was 29 $\pm$ 2.6 weeks; median birth weight was 1200 g. 95% had neonatal respiratory distress (mostly hyaline membrane disease).
• Treatment Response:
  • Clinical Improvement: 77% (46/60) after first-line treatment.
  • Echocardiographic Closure: 83.3% (50/60) achieved closure, mostly within 3 days.
  • Drug Usage: Paracetamol (73.3%) vs. Ibuprofen (26.7%).
• Predictors of Success:
  • Gestational Age $\ge$ 28 weeks: Strong predictor of closure (OR = 5.9; 95% CI: 1.7–20.2).
  • Antenatal Corticosteroids: Significantly associated with clinical improvement (OR = 2.3) and a trend toward closure (OR = 5.1).
  • Failure Predictors: Hypotrophy and absence of antenatal corticosteroids were significantly associated with treatment failure.
• Complications & Mortality:
  • Mortality Rate: 35% (21/60).
  • Mortality Drivers: Gestational age < 28 weeks was the strongest predictor of death (OR = 5.0; 82.4% mortality in this group vs. 16.3% in older infants).
  • Impact of Treatment: Lack of clinical improvement (OR = 3.7) and lack of echocardiographic closure (OR = 4.5) after the first course were independently associated with higher mortality.
  • Other Morbidities: IVH occurred in 36.7% (significantly linked to GA < 28 weeks); NEC in 11.7%.

5. Significance and Implications

• Clinical Practice: The findings support the use of paracetamol as a highly effective first-line alternative to ibuprofen, particularly given the high closure rates observed (83.3%).
• Prognostic Value: Gestational age (<28 weeks) and antenatal corticosteroid exposure are critical prognostic indicators. Clinicians should anticipate lower response rates and higher mortality in extremely preterm infants, potentially necessitating earlier or more aggressive intervention strategies.
• Screening Protocols: The study highlights that relying on clinical symptoms often leads to delayed diagnosis. It advocates for systematic echocardiographic screening in high-risk preterm infants to facilitate pre-symptomatic treatment, which is linked to reduced mortality.
• Limitations: The authors acknowledge the study's limitations, including its retrospective nature, single-center design, small sample size (limiting statistical power for some subgroups), and lack of long-term neurodevelopmental follow-up.
• Future Directions: The study calls for prospective, multicenter randomized trials to compare paracetamol and ibuprofen directly and to establish standardized screening protocols for extremely preterm infants.

In conclusion, this study reinforces that PDA management in preterm infants requires a risk-adapted approach, where gestational age and prenatal care (corticosteroids) dictate the likelihood of therapeutic success and survival.